Shengxiang Biotech announced that the company reviewed and approved the repurchase plan on June 23, 2026. It is expected to repurchase 50 million yuan to 10 million yuan of shares, and the repurchase price will not exceed 22 yuan/share. The repurchase was completed on July 17. The actual repurchase of 6.827 million shares, accounting for 1.18% of the total share capital, amounting to 999.807 million yuan, and the price range was 13.79 yuan/share - 15.64 yuan/share. This repurchase uses its own funds and will not affect the company's control and listing position. The share repurchase will be used for employee stock ownership plans or equity incentives. If not implemented within three years, the capital reduction will be cancelled in accordance with the law.

Shengxiang Biotech announced that the company reviewed and approved the repurchase plan on June 23, 2026. It is expected to repurchase 50 million yuan to 10 million yuan of shares, and the repurchase price will not exceed 22 yuan/share. The repurchase was completed on July 17. The actual repurchase of 6.827 million shares, accounting for 1.18% of the total share capital, amounting to 999.807 million yuan, and the price range was 13.79 yuan/share - 15.64 yuan/share. This repurchase uses its own funds and will not affect the company's control and listing position. The share repurchase will be used for employee stock ownership plans or equity incentives. If not implemented within three years, the capital reduction will be cancelled in accordance with the law.